Λεπτομέρειες βιβλιογραφικής εγγραφής
| Τίτλος: |
Pharmacological blood-pressure lowering for the prevention of cardiovascular disease and death across the full spectrum of chronic kidney disease severity: an individual-participant data meta-analysis |
| Συγγραφείς: |
Zeng G, Bidel Z, Yang Q, Canoy D, Woodward M, Lewis J, Kjeldsen SE, Cushman WC, Yuan J, Teo K, Davis BR, Chalmers J, Pepine CJ, Rahimi K, Nazarzadeh M, Adler A, Agodoa L, Algra A, Anderson C, Asselbergs FW, Baigent C, Beckett NS, Berge E, Black H, Boersma E, Brenner BM, Brouwers FPJ, Brown M, Brugts JJ, Bulpitt CJ, Byington RP, Collins R, Cutler J, Devereaux RB, Dwyer JP, Estacio R, Fagard R, Fox K, Fukui T, van Gilst WH, Gupta AK, Holman RR, Imai Y, Ishii M, Julius S, Kanno Y, Kostis J, Kuramoto K, Lanke J, Lewis E, Lewis JB, Lievre M, Lindholm LH, Lubsen J, Lueders S, MacMahon S, Malacco E, Mancia G, Matsuzaki M, McManus RJ, Mehlum MH, Neal B, Nissen S, Ogawa H, Ogihara T, Ohkubo T, Palmer CR, Patel A, Perkovic V, Pfeffer MA, Pitt B, Poulter NR, Rakugi H, Reboldi G, Reid C, Remuzzi G, Rodgers A, Rothwell P, Ruggenenti P, Salimi-Khorshidi G, Saruta T, Schrader J, Schrier R, Sever P, Sleight P, Staessen JA, Sundstrom J, Suzuki H, Thijs L, Turnbull F, Ueshima K, Umemoto S, Verdecchia P, Viberti G, Wachtell K, Wang J, Whelton P, Wing L, Yui Y, Yusuf S, Zanchetti A, de Zeeuw D, Zhang Z-Y |
| Πηγή: |
The Lancet, 25 April 2026 |
| Στοιχεία εκδότη: |
Elsevier BV |
| Έτος έκδοσης: |
2026 |
| Συλλογή: |
Newcastle University Library ePrints Service |
| Περιγραφή: |
© 2026 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Background: Individuals with chronic kidney disease (CKD), particularly those at more advanced stages, have been systematically under-represented in randomised controlled trials (RCTs) of blood-pressure-lowering treatment due to safety concerns, leading to a persistent paucity of evidence for cardiovascular risk management in this high-risk group. We investigated the effect of blood-pressure-lowering treatment on the risk of major cardiovascular disease and death across the full spectrum of CKD stages and by key clinical subgroups. Methods: We conducted a one-stage meta-analysis of individual-participant data from RCTs in which participants were randomly assigned to a blood-pressure-lowering therapy versus a comparator. We used RCTs collated in the Blood Pressure Lowering Treatment Trialists’ Collaboration dataset, published at any time in any language, which were eligible for inclusion if they had at least 1000 person-years of follow-up per arm, baseline blood-pressure and creatinine measurements, and time-to-event outcomes; those with unclear randomisation procedures or restricted to heart failure or acute care settings were excluded. Participants with a documented history of heart failure or extreme creatinine values were excluded. No age criteria were applied. The primary outcome was major cardiovascular events, defined as a composite of fatal or non-fatal stroke, ischaemic heart disease, or hospitalisation for, or death from, heart failure. Relative treatment effects were estimated with a stratified Cox proportional hazards model. Heterogeneity of treatment effects was evaluated across prespecified subgroups defined by CKD status, CKD stage (1–5), diabetes, proteinuria, and baseline blood pressure. A stratified network meta-analysis was performed to examine whether treatment effects differed by defined subgroups within each of five principal antihypertensive drug classes. The systematic review was ... |
| Τύπος εγγράφου: |
article in journal/newspaper |
| Περιγραφή αρχείου: |
application/pdf |
| Γλώσσα: |
unknown |
| Relation: |
https://eprints.ncl.ac.uk/311690; https://eprints.ncl.ac.uk/fulltext.aspx?url=311690/CAE8635F-E367-4C49-8376-52BC65747830.pdf&pub_id=311690 |
| Διαθεσιμότητα: |
https://eprints.ncl.ac.uk/311690 |
| Rights: |
https://creativecommons.org/licenses/by/4.0/ |
| Αριθμός Καταχώρησης: |
edsbas.C2B5B4EE |
| Βάση Δεδομένων: |
BASE |